Tohoku University. Research Profiles


New Developments in Bone Regenerative Therapy



Octacalcium phosphate/collagen composites (OCP/Col: Bonarc), a bone regenerative material commercialized in 2019, outperforms the bone regeneration of existing bone substitutes and is cost-effective and easy to use. Recently, we have demonstrated that the addition of teriparatide (TPTD: a parathyroid hormone for the treatment of osteoporosis) to OCP/Col, or improvements in the manufacturing process of OCP/Col, would expand their use for intractable bone defects and bone augmentation, which is difficult to treat.

Targeted Application(s)/Industry

As a medical devise of bone regenerative material, expansion of application in various bone defect (orthopedic surgery, neurosurgery, etc.) and overseas expansion would be expected. Furthermore, as a combination product based on OCP/Col would provide a therapeutic alternative for difficult bone defects or urgent surgery.


Bone Regenerative Engineering Laboratory, Regenerative and Biomedical Engineering Division, Graduate School of Biomedical Engineering

KAMAKURA Shinji , Professor
Doctor of Dental Science


Related Information

Kawai T, Kamakura S, Matsui K, et al; Clinical study of octacalcium phosphate and collagen composite in oral and maxillofacial surgery. J Tissue Eng 11:2041731419896449, 2020 doi: 10.1177/2041731419896449
Matsui K, et al; Segmental bone reconstruction by octacalcium phosphate collagen composites with teriparatide. Tissue Eng Part A 27: 561-571, 2021 DOI: 10.1089/ten.TEA.2020.0150
Yanagisawa T, et al; Influence of pre-freezing conditions of octacalcium phosphate and collagen composite for reproducible appositional bone formation. J Biomed Mater Res Part B 108: 2827-2834, 2020 DOI: 10.1002/jbm.b.34613